Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Next Previous
Search
Trial Profile

A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms REVEAL
  • Sponsors Abbott GmbH & Co. KG

    • Most Recent Events

    • 01 Jun 2022 Results by deriving data from REVEAL assessing differences in trial-observed TWPI across PASI response cohorts, published in the Journal of Dermatological Treatment
    • 01 Jan 2018 Results comparing Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis in patients data from M10-114, M10-315, REVEAL and CHAMPION trials (n=1692), published in the Value in Health
    • 05 Nov 2016 Results of a post-hoc analysis assessing efficacy of adalimumab by body region and regional response and quality of life relationship, published in the American Journal of Clinical Dermatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top